Welcome to our dedicated page for Erasca news (Ticker: ERAS), a resource for investors and traders seeking the latest updates and insights on Erasca stock.
Erasca, Inc. develops precision oncology therapies for cancers driven by the RAS/MAPK pathway. News on ERAS commonly centers on its RAS-targeting pipeline, including ERAS-0015, an investigational oral pan-RAS molecular glue evaluated in RAS-mutant solid tumors, and ERAS-4001, an oral pan-KRAS inhibitor for KRAS-mutant solid tumors.
Company updates frequently cover Phase 1 clinical data, dose-escalation results, trial collaborations and supply agreements, intellectual-property protection, development rights, public offering activity, financial results, and healthcare conference presentations. Recurring cancer settings in company disclosures include non-small cell lung cancer, pancreatic adenocarcinoma, colorectal cancer, and other RAS-mutant solid tumors.
Erasca (Nasdaq: ERAS) announced management will present and hold one-on-one investor meetings at two February 2026 conferences: Guggenheim Emerging Outlook: Biotech Summit (Feb 11-12) and Oppenheimer 36th Annual Healthcare Life Sciences Conference (Feb 25-26).
Fireside chat times: Feb 12 at 1:00 PM ET (Guggenheim) and Feb 26 at 11:20 AM ET (Oppenheimer). Live audio webcasts and archived replays will be available at Erasca.com/events for 30 days following each webcast.
Erasca (Nasdaq: ERAS) closed an upsized public offering of 25,875,000 shares of common stock on January 23, 2026, which included 3,375,000 shares sold pursuant to the underwriters' full exercise of their option.
The shares were sold at $10.00 per share, generating approximately $258.8 million in gross proceeds before underwriting discounts, commissions, and offering expenses. All shares were sold by Erasca.
Erasca intends to use net proceeds, together with existing cash and marketable securities, to fund research and development of its product candidates, development programs, working capital, and other general corporate purposes.
Erasca (Nasdaq: ERAS) priced an upsized public offering of 22,500,000 shares of common stock at $10.00 per share, generating expected gross proceeds of $225.0 million. The company granted the underwriters a 30‑day option to purchase up to an additional 3,375,000 shares at the offering price, less underwriting discounts and commissions.
The offering is expected to close on January 23, 2026, subject to customary closing conditions. Net proceeds, together with existing cash and securities, are intended to fund research and development of product candidates, other development programs, and for working capital and general corporate purposes.
Erasca (Nasdaq: ERAS) announced a proposed underwritten public offering of $150.0 million of common stock with a 30-day underwriter option to purchase up to an additional $22.5 million of shares. The company said it will use net proceeds together with existing cash and marketable securities to fund research and development of product candidates, other development programs, and for working capital and general corporate purposes. The offering will be made under a shelf registration statement declared effective on August 22, 2025, and a preliminary prospectus supplement will be filed with the SEC. There is no assurance the offering will be completed or as to final size or terms.
Erasca (NASDAQ: ERAS) reported early Phase 1 clinical progress for its RAS franchise. ERAS-0015 showed ongoing responses including two confirmed partial responses and one unconfirmed partial response observed at 8 mg QD, with favorable safety (no dose-limiting toxicities) and linear pharmacokinetics; data cutoff was January 7, 2026. INDs for ERAS-0015 and ERAS-4001 were cleared in May 2025. Initial Phase 1 monotherapy topline data for ERAS-0015 are planned for H1 2026, with expansion and combination cohorts in H2 2026 and additional data in 2027. ERAS-4001 monotherapy topline data are planned for H2 2026 with cohorts in 2027.
Erasca (Nasdaq: ERAS) announced it will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
Management will present on Tuesday, January 13, 2026 at 1:30 PM PT, participate in one-on-one investor meetings, and provide a live audio webcast at Erasca.com/events. An archived replay will be available for 30 days after the webcast.
Erasca (Nasdaq: ERAS) will present at the 8th Annual Evercore Healthcare Conference in Coral Gables, FL.
Management will take part in a fireside chat on Wednesday, December 3, 2025 at 10:25 AM ET, hold one-on-one investor meetings, and provide a live audio webcast at Erasca.com/events. An archived replay will be available for 30 days after the webcast.
Erasca (Nasdaq: ERAS) reported third quarter 2025 business updates and financial results on Nov 12, 2025. Key items: a U.S. composition-of-matter patent (No. 12,458,647) was issued for the pan-RAS molecular glue ERAS-0015 covering compositions until September 2043; initial Phase 1 monotherapy data for ERAS-0015 and the pan-KRAS inhibitor ERAS-4001 are expected in 2026; and Robert Shoemaker, Ph.D., was promoted to chief scientific officer.
Financials: cash, cash equivalents, and marketable securities were $362.4M as of Sept 30, 2025 (down from $440.5M at Dec 31, 2024) and are expected to fund operations into H2 2028. Q3 R&D expense was $22.5M; G&A was $10.1M; net loss was $30.6M or $(0.11) per share.
Erasca (Nasdaq: ERAS) announced that the U.S. Patent and Trademark Office issued Patent No. 12,458,647, titled “Macrocyclic Derivative And Use Thereof,” covering the composition of matter for the pan‑RAS molecular glue ERAS-0015 and related compositions.
The patent provides protection through September 2043, subject to possible patent term adjustments or extensions. The company noted it in‑licensed the program in May 2024 and said initial Phase 1 monotherapy data for ERAS-0015 and for pan‑KRAS inhibitor ERAS-4001 are expected in 2026.
Erasca (Nasdaq: ERAS) announced management will participate in investor conferences and one-on-one meetings in November 2025. Events and times:
- Guggenheim 2nd Annual Healthcare Innovation Conference — Boston, Nov 10-12; Fireside chat on Nov 11 at 2:00 pm ET.
- Stifel 2025 Healthcare Conference — New York, Nov 11-13; Fireside chat on Nov 12 at 1:20 pm ET.
- Jefferies Global Healthcare Conference — London, Nov 17-20; Fireside chat on Nov 19 at 10:30 am GMT.